Intranasal foralumab was well-tolerated with no adverse reactions or laboratory abnormalities after 6 months of therapy and the patient chose to remain on therapy
Data show sustained inhibition of microglial activation as assessed by Positron Emission Tomography (PET) along with downregulation of pro-inflammatory cytokines associated with brain inflammation, as well as stabilization of disease as measured by clinical assessments
Based on these observations the FDA has allowed a second patient to receive intranasal foralumab therapy under a separate Single-Patient Expanded Access IND (SPIND)
Tiziana to hold Key Opinion Leader (KOL) event to discuss the data on March 14th, 2022, 11 a.m. ET
These data will be presented in a virtual Key Opinion Leader (KOL) event hosted by Tiziana on March 14th, 2022, at 11 a.m. ET entitled “Foralumab Clinical Update in Multiple Sclerosis; A Landmark Study with Intranasal Immunotherapy” featuring four Key Opinion Leaders and a live Q&A session. Further details to follow. Register here: https://lifesci.events/TLSA
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.